Cargando…

PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy

In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nechifor-Boilă, Ioan Alin, Loghin, Andrada, Nechifor-Boilă, Adela, Decaussin-Petrucci, Myriam, Voidăzan, Septimiu, Chibelean, Bogdan Călin, Martha, Orsolya, Borda, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146852/
https://www.ncbi.nlm.nih.gov/pubmed/33925149
http://dx.doi.org/10.3390/life11050404
_version_ 1783697493187362816
author Nechifor-Boilă, Ioan Alin
Loghin, Andrada
Nechifor-Boilă, Adela
Decaussin-Petrucci, Myriam
Voidăzan, Septimiu
Chibelean, Bogdan Călin
Martha, Orsolya
Borda, Angela
author_facet Nechifor-Boilă, Ioan Alin
Loghin, Andrada
Nechifor-Boilă, Adela
Decaussin-Petrucci, Myriam
Voidăzan, Septimiu
Chibelean, Bogdan Călin
Martha, Orsolya
Borda, Angela
author_sort Nechifor-Boilă, Ioan Alin
collection PubMed
description In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi-institutional study was performed within the departments of urology and pathology at the Mureș County Hospital, Romania, and Centre Hospitalier Lyon Sud, France. Sixty-nine patients with MIBC were included, for whom tumor histology (conventional versus histological variant/differentiation), tumor extension (T), lymph node involvement (N), and distant metastases (M) were recorded. PD-L1 immunostaining was performed using the 22C3 clone and was interpreted using the combined positive score (CPS) as recommended (Dako Agilent, Santa Clara, CA, USA). Positive PD-L1 immunostaining was more prevalent among UCs with squamous differentiation compared to conventional UCs and trended towards an improved OS (p = 0.366). We found the T stage to be a risk factor for poor survival in PD-L1-positive patients (HR 2.9, p = 0.021), along with the N stage in PD-L1-negative patients (HR 1.98, p = 0.007). No other clinicopathological factor was found to be significantly associated with PD-L1 positivity. Thus, we confirm the need for PD-L1 immunostaining prior to initiating immune checkpoint inhibitor therapy for a more accurate assessment of the patients’ chances of responding to treatment.
format Online
Article
Text
id pubmed-8146852
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81468522021-05-26 PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy Nechifor-Boilă, Ioan Alin Loghin, Andrada Nechifor-Boilă, Adela Decaussin-Petrucci, Myriam Voidăzan, Septimiu Chibelean, Bogdan Călin Martha, Orsolya Borda, Angela Life (Basel) Article In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi-institutional study was performed within the departments of urology and pathology at the Mureș County Hospital, Romania, and Centre Hospitalier Lyon Sud, France. Sixty-nine patients with MIBC were included, for whom tumor histology (conventional versus histological variant/differentiation), tumor extension (T), lymph node involvement (N), and distant metastases (M) were recorded. PD-L1 immunostaining was performed using the 22C3 clone and was interpreted using the combined positive score (CPS) as recommended (Dako Agilent, Santa Clara, CA, USA). Positive PD-L1 immunostaining was more prevalent among UCs with squamous differentiation compared to conventional UCs and trended towards an improved OS (p = 0.366). We found the T stage to be a risk factor for poor survival in PD-L1-positive patients (HR 2.9, p = 0.021), along with the N stage in PD-L1-negative patients (HR 1.98, p = 0.007). No other clinicopathological factor was found to be significantly associated with PD-L1 positivity. Thus, we confirm the need for PD-L1 immunostaining prior to initiating immune checkpoint inhibitor therapy for a more accurate assessment of the patients’ chances of responding to treatment. MDPI 2021-04-28 /pmc/articles/PMC8146852/ /pubmed/33925149 http://dx.doi.org/10.3390/life11050404 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nechifor-Boilă, Ioan Alin
Loghin, Andrada
Nechifor-Boilă, Adela
Decaussin-Petrucci, Myriam
Voidăzan, Septimiu
Chibelean, Bogdan Călin
Martha, Orsolya
Borda, Angela
PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
title PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
title_full PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
title_fullStr PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
title_full_unstemmed PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
title_short PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy
title_sort pd-l1 expression in muscle invasive urothelial carcinomas as assessed via immunohistochemistry: correlations with specific clinical and pathological features, with emphasis on prognosis after radical cystectomy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146852/
https://www.ncbi.nlm.nih.gov/pubmed/33925149
http://dx.doi.org/10.3390/life11050404
work_keys_str_mv AT nechiforboilaioanalin pdl1expressioninmuscleinvasiveurothelialcarcinomasasassessedviaimmunohistochemistrycorrelationswithspecificclinicalandpathologicalfeatureswithemphasisonprognosisafterradicalcystectomy
AT loghinandrada pdl1expressioninmuscleinvasiveurothelialcarcinomasasassessedviaimmunohistochemistrycorrelationswithspecificclinicalandpathologicalfeatureswithemphasisonprognosisafterradicalcystectomy
AT nechiforboilaadela pdl1expressioninmuscleinvasiveurothelialcarcinomasasassessedviaimmunohistochemistrycorrelationswithspecificclinicalandpathologicalfeatureswithemphasisonprognosisafterradicalcystectomy
AT decaussinpetruccimyriam pdl1expressioninmuscleinvasiveurothelialcarcinomasasassessedviaimmunohistochemistrycorrelationswithspecificclinicalandpathologicalfeatureswithemphasisonprognosisafterradicalcystectomy
AT voidazanseptimiu pdl1expressioninmuscleinvasiveurothelialcarcinomasasassessedviaimmunohistochemistrycorrelationswithspecificclinicalandpathologicalfeatureswithemphasisonprognosisafterradicalcystectomy
AT chibeleanbogdancalin pdl1expressioninmuscleinvasiveurothelialcarcinomasasassessedviaimmunohistochemistrycorrelationswithspecificclinicalandpathologicalfeatureswithemphasisonprognosisafterradicalcystectomy
AT marthaorsolya pdl1expressioninmuscleinvasiveurothelialcarcinomasasassessedviaimmunohistochemistrycorrelationswithspecificclinicalandpathologicalfeatureswithemphasisonprognosisafterradicalcystectomy
AT bordaangela pdl1expressioninmuscleinvasiveurothelialcarcinomasasassessedviaimmunohistochemistrycorrelationswithspecificclinicalandpathologicalfeatureswithemphasisonprognosisafterradicalcystectomy